Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin

P. Zarogoulidis, T. Kontakiotis, V. Zarogoulidou, E. Eleftheriadou, I. Sapardanis, D. Gioulekas, K. Zarogoulidis (Exohi, Thessaloniki, Greece)

Source: Annual Congress 2010 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Thematic Poster Session
Number: 5052

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Zarogoulidis, T. Kontakiotis, V. Zarogoulidou, E. Eleftheriadou, I. Sapardanis, D. Gioulekas, K. Zarogoulidis (Exohi, Thessaloniki, Greece). Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin. Eur Respir J 2010; 36: Suppl. 54, 5052

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007

Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020

Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy>
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018

A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 781s
Year: 2006

The effectiveness of pegfilgrastim in preventing leucopenia in patients with lung cancer under chemotherapy
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy
Source: Eur Respir J 2016; 48: 861-872
Year: 2016



Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020



Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer
Source: Eur Respir J 2006; 27: 1183-1189
Year: 2006



Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016


The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017

Pharmacokinetic study of aerosolized gemcitabine in non-small-cell lung cancer
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008

A prospective study on lung toxicity in patients treated with paclitaxel and carboplatin
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001